Search Results - christophe+marchand

3 Results Sort By:
Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues
Summary: NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents. Description of Technology: Topoisomerase enzymes play an important role in cancer progression by controlling changes...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Barry O'Keefe, Lauren Krumpe, Johan Rosengren, Ingrid Schroeder, Alan Bermingham, Christophe Marchand, Kirk Gustafson, Brice Wilson, Yves Pommier
Keywords(s): CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics
Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase
Abstract: Integrase strand transfer inhibitors (“INSTIs”) are currently in use as a component of prophylactic antiretroviral therapy for preventing HIV-1 infection from progressing to AIDS. Three INSTIs are approved by the FDA for inclusion in antiretroviral regiments: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). Clinicians have already...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Xue Zhao, Terrence Burke, Yves Pommier, Stephen Hughes, Mathieu Metifiot, Stephen Smith, Barry Johnson, Christophe Marchand
Keywords(s): dolutegravir, drug resistant HIV, elvitegravir, HIV therapy, Integrase, raltegravir, strand transfer
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing
Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer
Summary: The National Cancer Institute (NCI) seeks licensees for a family of novel furoquinolinedione derivatives that inhibit tyrosyl-DNA phosphodiesterase 2 (TDP2) as cancer therapeutics. Description of Technology: Tyrosyl-DNA phosphodiesterase 2 (TDP2) is an enzyme that plays a critical role in repairing nucleic acid lesions, namely by repairing...
Published: 1/12/2026   |   Updated: 8/2/2023   |   Inventor(s): Christophe Marchand, Lin-kun An, Yves Pommier
Keywords(s): CANCER, Combination Therapies, Pommier, therapeutic, Topoisomerase 2 (TOP2), Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics